Company / Cash per Share
Regeneron Pharmaceuticals Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$27.42
FY2025
5-year range
$19.14 / $27.42
FY2021-FY2025
Trend
+25.1%
vs FY2024
Sector context
#7 of 205
Health Care
What the data says
Among 205 Health Care companies, Regeneron Pharmaceuticals is in the top 3% for cash per share. Cash per Share returned to growth in FY2025 after 2 years of decline, reaching $27.42.
Based on SEC 10-K filings.
27.42 in FY2025 with a 5-year CAGR of +14.2%. Top quartile in the Health Care sector.
Improved from $24.33 to $27.42 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +3.0%
- 5-Year CAGR
- +14.2%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 205This company $27.42 Sector average $72.93
▼
-62.4% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 25.1% year-over-year.
- Ranks #7 out of 205 companies in the Health Care sector.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.42 | +25.1% |
| FY2024 | $21.92 | -9.9% |
| FY2023 | $24.33 | -2.9% |
| FY2022 | $25.07 | +31.0% |
| FY2021 | $19.14 | +35.8% |
| FY2020 | $14.09 | +1.0% |
| FY2019 | $13.96 | +10.6% |
| FY2018 | $12.62 | +78.9% |
| FY2017 | $7.05 | +49.5% |
| FY2016 | $4.72 | -35.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026